In reply
We thank Dr Kahana for his letter and comments regarding the article entitled, “Prevention of Corticosteroid-Induced Intraocular Pressure Elevation From ISV-205.”
The drug ISV-205 was developed with the proprietary delivery vehicle, DuraSite (InSite Vision Incorporated), to deliver sufficient concentrations of diclofenac (the active ingredient) into the anterior chamber to prevent the corticosteroid alteration of the trabecular meshwork. Prior research results of this formulation remain proprietary.